Scholar Rock Holding (SRRK) Share-based Compensation (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Share-based Compensation of $204.5 million for Q1 2026, up 1424.53% year-over-year from $13.4 million in Q1 2025, and up 952.8% quarter-over-quarter from $19.4 million in Q4 2025.
Analysis
Scholar Rock Holding (SRRK) Share-based Compensation (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Share-based Compensation history runs 10 years deep, the most recent figure standing at $204.5 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 1424.53% year-over-year to $204.5 million; the TTM figure through Mar 2026 stood at $204.5 million (up 388.3% YoY), while the FY2025 annual figure was $153.7 million, up 98.56% from the prior year.
- Share-based Compensation for Q1 2026 stood at $204.5 million, up from $19.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $204.5 million in Q1 2026, with the low at $6.2 million in Q4 2022.
- The 5-year median for Share-based Compensation is $8.2 million (2024), against an average of $30.9 million.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation dropped 9.64% in 2023, then jumped 1689.63% in 2025.
- Scholar Rock Holding's Share-based Compensation stood at $6.2 million in 2022, then rose by 12.75% to $7.0 million in 2023, then jumped by 36.7% to $9.5 million in 2024, then soared by 104.41% to $19.4 million in 2025, then soared by 952.8% to $204.5 million in 2026.
- Business Quant data shows SRRK's Share-based Compensation at $204.5 million in Q1 2026, $19.4 million in Q4 2025, and $172.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Scholar Rock Holding | 7.26 Bn | 7.26 Bn | - | 194.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 194.21 Mn |
| Mar 31, 2026 | 18.25 Mn |
| Dec 31, 2025 | 19.42 Mn |
| Sep 30, 2025 | 172.70 Mn |
| Jun 30, 2025 | 24.43 Mn |
| Mar 31, 2025 | 13.41 Mn |
| Dec 31, 2024 | 9.50 Mn |
| Sep 30, 2024 | 9.67 Mn |
| Jun 30, 2024 | 9.31 Mn |
| Mar 31, 2024 | 9.05 Mn |
| Dec 31, 2023 | 6.95 Mn |
| Sep 30, 2023 | 7.42 Mn |
| Jun 30, 2023 | 7.84 Mn |
| Mar 31, 2023 | 7.54 Mn |
| Dec 31, 2022 | 6.17 Mn |
| Sep 30, 2022 | 7.92 Mn |
| Jun 30, 2022 | 1.00 Bn |
| Mar 31, 2022 | 6.83 Mn |
| Dec 31, 2021 | 6.10 Mn |
| Sep 30, 2021 | 6.15 Mn |